Avocet targets growth after setback 18/03/2010
Gold producer Avocet Mining hopes its Wega acquisition will take 2010 group output to 200,000 oz after a flat nine months.
Bombed-out anti-viral treatment developer Henderson Morley is talking to potential buyers of parts or all of its business.
The Birmingham-based company, which floated on AIM six years ago to develop its patented Ionic Contra Viral Therapy (ICVT) as a treatment for herpes, warts, verrucae and kindred ailments, lost £548,000 in the six months to last October after a £45,000 tax credit on negligible turnover of £686. Henderson Morley ended the period with £875,000 cash, down from £1.4 million a year earlier and £1.5 million at the end of its full-year last April.
Executive chairman Andrew Knight enthuses that Henderson Morley has ‘the strongest pipeline, with the greatest number of patents, both granted and under application, in the history of the company’, which was founded 12 years ago. But he discloses that a strategic review, started last year to enhance shareholder value, has led to talks with a shortlist of other companies in the UK and overseas, which ‘may or may not lead to an offer being made for some or all of the company’s businesses’.
Eight years ago Henderson Morley shares traded on Ofex (now PLUS) at more than 6p, but, after their 4p AIM float in 2001, they eventually plunged to 0.43p in 2005 before surging up to 5.78p in March 2006. Since then, however, they have slipped to 1.55p, up 0.08p today.
Their current prospects depend on whatever deal Knight can negotiate.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The report reveals the top-earning chief executives and remuneration levels at AIM's most profitable and fastest-growing companies. It also examines constituent parts, including basic salary, bonus, pensions, benefits and share-based payments. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Advertisement
Gold producer Avocet Mining hopes its Wega acquisition will take 2010 group output to 200,000 oz after a flat nine months.
AIM shell China Evoline is understood to be contemplating the injection of some Chinese mining assets.
Small and medium sized company financier Ultimate Finance has increased first-half profits 36 per cent to £191,000 pre-tax.